变应性鼻炎(allergic rhinitis,AR)或称过敏性鼻炎,是一种由特应性个体暴露于过敏原(变应原)后,主要由免疫球蛋白E(immunoglobulin E,IgE)介导的鼻黏膜非感染性慢性炎性疾病,以鼻塞、鼻痒、喷嚏、流涕为主要临床特征。近年来全球AR的发病率逐年增加,流行病学研究,AR在世界范围内的平均发病率为10%~20%,部分国家高达40%。我国研究显示,2005~2011年成人AR患病率从11.1%上升到17.6%[1]。AR可伴发变应性结膜炎、鼻窦炎、鼻息肉、分泌性中耳炎等,且是变应性哮喘的独立危险因素。2001年世界卫生组织制订了变应性鼻炎及其对哮喘的影响(allergic rhinitis and its impact on asthma,ARIA)的全球诊疗参考文件,至今已经进行多次修订[2]。
目的:探讨度普利尤单抗(Dupilumab)治疗中重度特应性皮炎(Atopic Dermatitis, AD)儿童患者的有效性及安全性。方法:本研究采用单中心前瞻性设计,纳入77例中重度AD儿童,均接受12周Dupilumab治疗。通过特应性皮炎评分(Scoring Atopic Dermatitis, SCORAD)、瘙痒症数值评定量表(Pruritus Numerical Rating Scale, P-NRS)、皮肤病生活质量指数(Dermatology Life Quality Index, DLQI)、患者湿疹自我监测(Patient-Oriented Eczema Measure, POEM)对病情进行评估。采用非参数秩检验分析治疗前后SCORAD、NRS、DLQI、POEM及过敏原血清总免疫球蛋白E (Total Immunoglobulin E, tIgE)及血常规等实验室指标。结果:本研究共纳入了77例完成12周Dupilumab治疗及随访的中重度AD儿童。与基线相比,第12周治疗后SCORAD、P-NRS、DLQI、POEM各量表评分较基线均显著下降(P Objective: To investigate the efficacy and safety of Dupilumab in the treatment of children with moderate to severe atopic dermatitis (AD). Method: This study adopted a single-center prospective design, enrolling 77 children with moderate-to-severe atopic dermatitis (AD) who received 12 weeks of Dupilumab treatment. Disease severity was evaluated using Scoring Atopic Dermatitis (SCORAD), Pruritus Numerical Rating Scale (P-NRS), Dermatology Life Quality Index (DLQI), and Patient-oriented Eczema Measure (POEM). Nonparametric rank tests were used to analyze pre- and post-treatment differences in SCORAD, P-NRS, DLQI, POEM scores, as well as laboratory indices including Total Immunoglobulin E (tIgE) in allergen-specific serum and blood routine parameters. Results: This study included 77 children with moderate-to-severe atopic dermatitis (AD) who completed 12 weeks of dupilumab treatment and follow-up. Compared with baseline, scores on the SCORAD, P-NRS, DLQI, and POEM scales significantly decreased at week 12 (all P < 0.001). Serum total IgE (tIgE) levels showed a statistically significant reduction from baseline (903 kU/L vs. 395 kU/L, P <
目的:探讨变应性鼻炎(AR)患儿的心理状况及其影响因素。方法:选取2023年6月至2024年12月在青岛大学附属医院变态反应科就诊的7~14岁AR患儿,收集人口学特征(年龄、体质指数)及临床特征(病程、AR分型、症状严重程度、合并哮喘情况)。采用抑郁–焦虑–压力量表(DASS-21)评估AR患儿心理状况,通过单因素分析和多因素Logistic回归分析探讨心理状态的影响因素。结果:AR患儿抑郁症状、焦虑症状阳性率分别为16.48%、19.23%。单因素分析显示:年龄大于12岁、病程大于1年、中重度鼻炎、持续性发作以及合并哮喘是抑郁、焦虑症状的影响因素(P Objective: Exploring the psychological status and influencing factors of children with allergic rhinitis (AR). Methods: In this study, children with AR aged 7 to 14 years with allergic rhinitis (AR) who visited the Abnormal (Allergic) Reaction Department, The Affiliated Hospital of Qingdao University from June 2023 to December 2024. Demographic characteristics (age, body mass index) and clinical characteristics (disease duration, AR classification, symptom severity, and comorbid asthma) were collected. The psychological status of AR patients was assessed using the depression-anxiety-stress scale (DASS-21), and the influencing factors of psychological status were explored through univariate analysis and multivariate logistic regression analysis. Results: The positive rates of depressive and anxiety symptoms in AR patients were 16.48% and 19.23%, respectively. Univariate analysis showed that age greater than 12 years, disease duration longer than 1 year, moderate-to-severe rhinitis, persistent episodes, and comorbid asthma were influencing factors for depressive and anxiety symptoms (P < 0.05). Multivariate analysis indicated that independent risk factors for depressive symptoms were age greater than 12 years, disease duration longer than 1 year, persistent episodes, and comorbid asthma;independent risk factors for anxiety symptoms
